ResearcherMayo ClinicNo recent work listed

Jingjing Lu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2841-3117; OpenAlex author ID A5013693577. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2019: 1 paper

Papers 1

Verteporfin- and sodium porfimer-mediated photodynamic therapy enhances pancreatic cancer cell death without activating stromal cells in the microenvironment. Co-author DOI 10.1117/1.jbo.24.11.118001 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Tayyaba Hasan · 1 shared paper, 2019 · strength 0.10
- Paper Verteporfin- and sodium porfimer-mediated photodynamic therapy enhances pancreatic cancer cell death without activating… DOI 10.1117/1.jbo.24.11.118001 ↗
Kenneth K. Wang MD · 1 shared paper, 2019 · strength 0.10
- Paper Verteporfin- and sodium porfimer-mediated photodynamic therapy enhances pancreatic cancer cell death without activating… DOI 10.1117/1.jbo.24.11.118001 ↗
Brian William Pogue · 1 shared paper, 2019 · strength 0.10
- Paper Verteporfin- and sodium porfimer-mediated photodynamic therapy enhances pancreatic cancer cell death without activating… DOI 10.1117/1.jbo.24.11.118001 ↗
Michael J. Levy · 1 shared paper, 2019 · strength 0.10
- Paper Verteporfin- and sodium porfimer-mediated photodynamic therapy enhances pancreatic cancer cell death without activating… DOI 10.1117/1.jbo.24.11.118001 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.